- On 27 June 2026, Precigen, Inc. (NasdaqGS:PGEN) was removed from several Russell value indexes, including the Russell 2000, 2500, 3000, 3000E, Small Cap, and Microcap Value benchmarks.
- This broad index removal can prompt portfolio rebalancing by passive funds, potentially reshaping who holds the stock and how it trades over time.
- We’ll now examine how Precigen’s removal from multiple Russell value benchmarks may influence its investment narrative and future investor focus.
The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Precigen Investment Narrative Recap
To own Precigen today, you need to believe PAPZIMEOS can scale from a single RRP indication into a sustainable commercial franchise, while the company manages losses and a limited cash runway. The broad Russell index removals may affect trading liquidity and short term volatility, but they do not directly change the main catalyst, which is PAPZIMEOS uptake, or the key risk around funding needs if revenue ramps more slowly than expected.
The most relevant recent announcement here is the May 2026 update confirming durable PAPZIMEOS responses and full FDA approval with seven years of exclusivity. That clinical and regulatory validation underpins the growth case at the same time as the index removals potentially shift the shareholder base toward more active investors, who are often more focused on execution milestones such as payer adoption, cash burn, and the path to breakeven.
Yet while PAPZIMEOS is progressing, investors should also be aware that any delay in reimbursement or patient pull through could still...
Read the full narrative on Precigen (it's free!)
Precigen's narrative projects $482.5 million revenue and $317.5 million earnings by 2029. This requires 148.1% yearly revenue growth and a $700.9 million earnings increase from -$383.4 million today.
Uncover how Precigen's forecasts yield a $12.45 fair value, a 118% upside to its current price.
Exploring Other Perspectives
Eight fair value estimates from the Simply Wall St Community span roughly US$0.52 to US$23.09 per share, underscoring how far apart views can be. When you set those against the central catalyst of PAPZIMEOS execution and the risk that slower uptake could extend losses, it becomes even more important to compare several perspectives on what could drive Precigen’s results.
Explore 8 other fair value estimates on Precigen - why the stock might be worth less than half the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Precigen research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Precigen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Precigen's overall financial health at a glance.
Want Some Alternatives?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Find 43 companies with promising cash flow potential yet trading below their fair value.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com